Screener
Enliven Therapeutics ELVN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 27,823 | 31,693 |
| Loss from operations | (27,823) | (31,693) |
| Other income (expense), net | ||
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
| Total other income (expense), net | 4,196 | 3,149 |
| Net loss | (23,627) | (28,544) |
| Other comprehensive income (loss): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's interest expense?
- Enliven Therapeutics (ELVN) reported interest expense of $4.2M in Q1 2026.
- How has Enliven Therapeutics's interest expense changed year-over-year?
- Enliven Therapeutics's interest expense increased by 31.3% year-over-year, from $3.2M to $4.2M.
- What is the long-term trend for Enliven Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Enliven Therapeutics's interest expense has grown at a 187.9% compound annual growth rate (CAGR), from $233K to $16.01M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Enliven Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude